抗生素使用增加抗菌性菌種，這本來就知道，RTI up to 2.4X, UTI up to 1.3X

Resistance Tied to Antibiotic Use

Resistance to a particular antibiotic is more likely among individuals who have received that agent than among those who have not; the effect may last a year.

Infectious disease specialists have long believed that the emergence of drug-resistant bacteria is directly related to the use and overuse of antibiotics. However, antibiotic use is still not limited appropriately in the primary care setting. What does this mean for the individual patient?

Researchers reviewed data from 24 studies describing the link between antibiotics prescribed in primary care and subsequent resistance to those antibiotics at the individual level. Meta-analyses were conducted of five studies focused on bacteria in the urinary tract (involving >14,000 individuals) and seven studies focused on the respiratory tract (involving >2600 individuals). All but one study in each analysis involved symptomatic patients rather than healthy volunteers.

In each meta-analysis, patients who received a given antibiotic were about 2.5 times more likely than those who did not to have resistance to that antibiotic during the first 2 to 3 months after treatment. The effect remained significant at 1 year (pooled odds ratios, 2.4 in respiratory tract studies and 1.3 in urinary tract studies).

Data on the emergence of methicillin-resistant Staphylococcus aureus showed a variable effect of previous antibiotic treatment, with associations seen for nasal colonization but not skin colonization.


Comment: This study contributes definitively to the concept that antibiotic use promotes resistance. The greatest effect was seen immediately after therapy, but resistance sometimes persisted, particularly in the respiratory tract, for at least a year. Increased dosage and treatment duration led to increased resistance rates. An accompanying editorial acknowledges the need to limit antibiotic use but emphasizes, as does a companion article, the need to offer incentives for the development of new antimicrobial agents.

— Stephen G. Baum, MD

Published in Journal Watch Infectious Diseases May 26, 2010

Citation(s):

Costelloe C et al. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: Systematic review and meta-analysis. BMJ 2010 May 18; 340:c2096. (http://dx.doi.org/10.1136/bmj.c2096)

So AD et al. Tackling antibiotic resistance. BMJ 2010 May 18; 340:c2071. (http://dx.doi.org/10.1136/bmj.c2071)

Morel CM and Mossialos E. Stoking the antibiotic pipeline. BMJ 2010 May 18; 340:c2115. (http://dx.doi.org/10.1136/bmj.c2115)


http://docs.google.com/fileview?id=0B278nGJMQBk7NTBmMWQ0YzQtZjY0Zi00NjU0LWJjYWYtNGY3NWZmODkzODBj&hl=en

留言

張貼留言

這個網誌中的熱門文章

即便是用IGRA, 有時也要等大於三個月才能決定TB contact

圖片
接觸TB後，TST大抵上2-12週轉陽，IGRA大抵上6-10週，但IGRA可以長到3個月以上 TB Tests Can Have a Lengthy Window Period Two studies suggest that interferon- release assay conversion sometimes occurs more than 3 months after exposure to active tuberculosis. Increasingly, interferon- release assays (IGRAs) are being used for diagnosing latent tuberculosis (TB). Although the tuberculin skin test (TST) traditionally used for this purpose converts to positive within 2 to 12 weeks after an individual is exposed to someone with active TB, the interval for IGRA conversion has remained unclear. Current guidelines recommend repeating an initially negative IGRA after 6 to 10 weeks, but this recommendation is not based on controlled studies. Two recent investigations address this issue. Anibarro and colleagues conducted a longitudinal prospective analysis among contacts of TB patients in Spain. The 152 contacts received a TST and an IGRA at first visit; for individuals with negative or conflicting results, t
閱讀完整內容

白宮為了掌控醫療費用，傾向大型醫療，個體戶勢必受挫

所以一旦政府介入，中外醫療提供者都傾向大型化…… independent practice -> dreaming 診所評鑑??應該擋住! http://www.medscape.com/viewarticle/727420 Physicians Say White House Should Not Write Off Small Practices August 24, 2010 — In a newly published article, the White House is advising physicians to accept a life in Big Medicine — as a hospital employee or member of a large group practice — in the wake of healthcare reform. Some leaders of organized medicine, however, are objecting to the government message. "We're not ready to write off the small practices," J. Fred Ralston Jr, MD, president of the American College of Physicians, told Medscape Medical News. "We think there needs to be more than one delivery model." "America is not a one-size-fits-all country," added M. Todd Williamson, MD, a neurologist from Lawrenceville, Georgia, and spokesperson for a coalition of medical societies opposed to the new healthcare reform law, now called the Affordable Care Act. Dr. Ralston and Dr.
閱讀完整內容

老美接受LTBI treatment的人，不到一半完治，和duration成正比

This study shows that although acceptance of LTBI treatment is relatively high (83%), the proportion completing is low (47%). When the product of these two proportions is calculated, we see that completion was achieved by only 39% of persons who were offered LTBI treatment. The major risk factor for noncompletion was being prescribed the 9-month INH regimen. As shown in Figure 1, when the proportions completing the three most commonly prescribed regimens are compared, it can be seen that there is an inverse relationship between length of the regimen prescribed and the proportion completing treatment. The increased completion that we observed with the 4-month rifampin regimen is consistent with previous reports.[18–20] It is of interest to note that if completion of the 9-month regimen were defined as completion of at least 6 months of INH, the noncompletion rate of the 9-month regimen, 42.9%, would have been almost identical to that of the 6-month regimen, 44.8%. Thus, prescribing the
閱讀完整內容